Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 718

1.

Smartphone measures of day-to-day behavior changes in children with autism.

Jones RM, Tarpey T, Hamo A, Carberry C, Lord C.

NPJ Digit Med. 2018 Aug 14;1:34. doi: 10.1038/s41746-018-0043-3. eCollection 2018.

PMID:
31304316
Free PMC Article
2.

Number of Circulating CD 73-Expressing Lymphocytes Correlates With Survival After Cardiac Arrest.

Ryzhov S, May T, Dziodzio J, Emery IF, Lucas FL, Leclerc A, McCrum B, Lord C, Eldridge A, Robich MP, Ichinose F, Sawyer DB, Riker R, Seder DB.

J Am Heart Assoc. 2019 Jul 2;8(13):e010874. doi: 10.1161/JAHA.118.010874. Epub 2019 Jun 25.

3.

Recognising the heterogeneity of autism.

Lord C.

Lancet Psychiatry. 2019 Jul;6(7):551-552. doi: 10.1016/S2215-0366(19)30220-2. No abstract available.

PMID:
31230673
4.

A decade of clinical development of PARP inhibitors in perspective.

Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.

Ann Oncol. 2019 Jun 20. pii: mdz192. doi: 10.1093/annonc/mdz192. [Epub ahead of print]

PMID:
31218365
5.

Pelvic fractures: experience of pelvic ring fractures at a major trauma centre.

Leach SET, Skiadas V, Lord CE, Purohit N.

Clin Radiol. 2019 Aug;74(8):649.e19-649.e26. doi: 10.1016/j.crad.2019.04.020. Epub 2019 May 29.

PMID:
31153596
6.

Beyond DNA repair: the novel immunological potential of PARP inhibitors.

Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.

Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.

PMID:
31131303
7.

Integrating Oral Health: Physician Assistant Education in 2017.

Glicken AD, Savageau JA, Flick TA, Lord CB, Harvan RA, Silk H.

J Physician Assist Educ. 2019 Jun;30(2):93-100. doi: 10.1097/JPA.0000000000000250.

PMID:
31124806
8.

Neurological Pupil Index and Pupillary Light Reflex by Pupillometry Predict Outcome Early After Cardiac Arrest.

Riker RR, Sawyer ME, Fischman VG, May T, Lord C, Eldridge A, Seder DB.

Neurocrit Care. 2019 May 8. doi: 10.1007/s12028-019-00717-4. [Epub ahead of print]

PMID:
31069659
9.

MIReAD, a minimum information standard for reporting arthropod abundance data.

Rund SSC, Braak K, Cator L, Copas K, Emrich SJ, Giraldo-Calderón GI, Johansson MA, Heydari N, Hobern D, Kelly SA, Lawson D, Lord C, MacCallum RM, Roche DG, Ryan SJ, Schigel D, Vandegrift K, Watts M, Zaspel JM, Pawar S.

Sci Data. 2019 Apr 25;6(1):40. doi: 10.1038/s41597-019-0042-5.

10.

Dissecting PARP inhibitor resistance with functional genomics.

Pettitt SJ, Lord CJ.

Curr Opin Genet Dev. 2019 Apr 4;54:55-63. doi: 10.1016/j.gde.2019.03.001. [Epub ahead of print] Review.

PMID:
30954761
11.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
12.

A Multisite Randomized Controlled Two-Phase Trial of the Early Start Denver Model Compared to Treatment as Usual.

Rogers SJ, Estes A, Lord C, Munson J, Rocha M, Winter J, Greenson J, Colombi C, Dawson G, Vismara LA, Sugar CA, Hellemann G, Whelan F, Talbott M.

J Am Acad Child Adolesc Psychiatry. 2019 Jan 24. pii: S0890-8567(19)30044-9. doi: 10.1016/j.jaac.2019.01.004. [Epub ahead of print]

PMID:
30768394
13.

Taking Sleep Difficulties Seriously in Children With Neurodevelopmental Disorders and ASD.

Lord C.

Pediatrics. 2019 Mar;143(3). pii: e20182629. doi: 10.1542/peds.2018-2629. Epub 2019 Feb 11. No abstract available.

PMID:
30745434
14.

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.

Menon M, Elliott R, Bowers L, Balan N, Rafiq R, Costa-Cabral S, Munkonge F, Trinidade I, Porter R, Campbell AD, Johnson ER, Esdar C, Buchstaller HP, Leuthner B, Rohdich F, Schneider R, Sansom O, Wienke D, Ashworth A, Lord CJ.

Sci Rep. 2019 Jan 17;9(1):201. doi: 10.1038/s41598-018-36447-4.

15.

How effective is LENA in detecting speech vocalizations and language produced by children and adolescents with ASD in different contexts?

Jones RM, Plesa Skwerer D, Pawar R, Hamo A, Carberry C, Ajodan EL, Caulley D, Silverman MR, McAdoo S, Meyer S, Yoder A, Clements M, Lord C, Tager-Flusberg H.

Autism Res. 2019 Apr;12(4):628-635. doi: 10.1002/aur.2071. Epub 2019 Jan 14.

PMID:
30638310
16.

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S.

J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11.

17.

Changing Developmental Trajectories of Toddlers With Autism Spectrum Disorder: Strategies for Bridging Research to Community Practice.

Wetherby AM, Woods J, Guthrie W, Delehanty A, Brown JA, Morgan L, Holland RD, Schatschneider C, Lord C.

J Speech Lang Hear Res. 2018 Nov 8;61(11):2615-2628. doi: 10.1044/2018_JSLHR-L-RSAUT-18-0028.

PMID:
30418491
18.

Variability in Autism Symptom Trajectories Using Repeated Observations From 14 to 36 Months of Age.

Kim SH, Bal VH, Benrey N, Choi YB, Guthrie W, Colombi C, Lord C.

J Am Acad Child Adolesc Psychiatry. 2018 Nov;57(11):837-848.e2. doi: 10.1016/j.jaac.2018.05.026. Epub 2018 Sep 5. Erratum in: J Am Acad Child Adolesc Psychiatry. 2019 May;58(5):553.

PMID:
30392625
19.

For Better or for Worse? Later Diagnoses of Autism Spectrum Disorder in Some Younger Siblings of Already Diagnosed Children.

Lord C.

J Am Acad Child Adolesc Psychiatry. 2018 Nov;57(11):822-823. doi: 10.1016/j.jaac.2018.08.008.

PMID:
30392621
20.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

21.

Ghrelin Receptor Agonist Rescues Excess Neonatal Mortality in a Prader-Willi Syndrome Mouse Model.

Rodriguez JA, Bruggeman EC, Mani BK, Osborne-Lawrence S, Lord CC, Roseman HF, Viroslav HL, Vijayaraghavan P, Metzger NP, Gupta D, Shankar K, Pietra C, Liu C, Zigman JM.

Endocrinology. 2018 Dec 1;159(12):4006-4022. doi: 10.1210/en.2018-00801.

PMID:
30380028
22.

Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.

Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG Jr.

Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29.

PMID:
30373918
23.

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2018 Oct 26;13(10):e0206729. doi: 10.1371/journal.pone.0206729. eCollection 2018.

24.

A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.

Quist J, Mirza H, Cheang MCU, Telli ML, O'Shaughnessy JA, Lord CJ, Tutt ANJ, Grigoriadis A.

Mol Cancer Ther. 2019 Jan;18(1):204-212. doi: 10.1158/1535-7163.MCT-18-0243. Epub 2018 Oct 10.

25.

Measuring treatment response in children with autism spectrum disorder: Applications of the Brief Observation of Social Communication Change to the Autism Diagnostic Observation Schedule.

Kim SH, Grzadzinski R, Martinez K, Lord C.

Autism. 2019 Jul;23(5):1176-1185. doi: 10.1177/1362361318793253. Epub 2018 Oct 10.

PMID:
30303398
26.

Synthetic Lethality and Cancer - Penetrance as the Major Barrier.

Ryan CJ, Bajrami I, Lord CJ.

Trends Cancer. 2018 Oct;4(10):671-683. doi: 10.1016/j.trecan.2018.08.003. Epub 2018 Sep 15. Review.

PMID:
30292351
27.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. Erratum in: J Clin Invest. 2018 Nov 1;128(11):5185.

28.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

29.

Autism spectrum disorder symptoms from ages 2 to 19 years: Implications for diagnosing adolescents and young adults.

Bal VH, Kim SH, Fok M, Lord C.

Autism Res. 2019 Jan;12(1):89-99. doi: 10.1002/aur.2004. Epub 2018 Aug 12.

30.

Autism spectrum disorder.

Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J.

Lancet. 2018 Aug 11;392(10146):508-520. doi: 10.1016/S0140-6736(18)31129-2. Epub 2018 Aug 2. Review.

PMID:
30078460
31.

Determinants of parent-delivered therapy interventions in children with cerebral palsy: A qualitative synthesis and checklist.

Lord C, Rapley T, Marcroft C, Pearse J, Basu A.

Child Care Health Dev. 2018 Sep;44(5):659-669. doi: 10.1111/cch.12592. Epub 2018 Jul 23.

PMID:
30033521
32.

Greater loss of horizontal force after a repeated-sprint test in footballers with a previous hamstring injury.

Lord C, Blazevich AJ, Drinkwater EJ, Ma'ayah F.

J Sci Med Sport. 2019 Jan;22(1):16-21. doi: 10.1016/j.jsams.2018.06.008. Epub 2018 Jun 20.

PMID:
30025916
33.

The shieldin complex mediates 53BP1-dependent DNA repair.

Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D.

Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18.

34.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

35.

CD177-mediated nanoparticle targeting of human and mouse neutrophils.

Miettinen HM, Gripentrog JM, Lord CI, Nagy JO.

PLoS One. 2018 Jul 10;13(7):e0200444. doi: 10.1371/journal.pone.0200444. eCollection 2018.

36.

Wild pigs as sentinels for hard ticks: A case study from south-central Florida.

Merrill MM, Boughton RK, Lord CC, Sayler KA, Wight B, Anderson WM, Wisely SM.

Int J Parasitol Parasites Wildl. 2018 Apr 30;7(2):161-170. doi: 10.1016/j.ijppaw.2018.04.003. eCollection 2018 Aug.

37.

Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.

Vinci M, Burford A, Molinari V, Kessler K, Popov S, Clarke M, Taylor KR, Pemberton HN, Lord CJ, Gutteridge A, Forshew T, Carvalho D, Marshall LV, Qin EY, Ingram WJ, Moore AS, Ng HK, Trabelsi S, H'mida-Ben Brahim D, Entz-Werle N, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Sunol M, Mora J, de Torres C, Cruz O, Carcaboso AM, Monje M, Mackay A, Jones C.

Nat Med. 2018 Aug;24(8):1204-1215. doi: 10.1038/s41591-018-0086-7. Epub 2018 Jul 2.

38.

Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

Ashworth A, Lord CJ.

Nat Rev Clin Oncol. 2018 Sep;15(9):564-576. doi: 10.1038/s41571-018-0055-6. Review.

PMID:
29955114
39.

Whole exome sequencing in the rat.

Foley JF, Phadke DP, Hardy O, Hardy S, Miller V, Madan A, Howard K, Kruse K, Lord C, Ramaiahgari S, Solomon GG, Shah RR, Pandiri AR, Herbert RA, Sills RC, Merrick BA.

BMC Genomics. 2018 Jun 20;19(1):487. doi: 10.1186/s12864-018-4858-8.

40.

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.

Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ.

Oncogene. 2018 Oct;37(43):5701-5718. doi: 10.1038/s41388-018-0368-z. Epub 2018 Jun 18.

41.

Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease.

Jia L, Chang X, Qian S, Liu C, Lord CC, Ahmed N, Lee CE, Lee S, Gautron L, Mitchell MC, Horton JD, Scherer PE, Elmquist JK.

Mol Metab. 2018 Aug;14:121-129. doi: 10.1016/j.molmet.2018.05.015. Epub 2018 May 23.

42.

Statistical Learning is Associated with Autism Symptoms and Verbal Abilities in Young Children with Autism.

Jones RM, Tarpey T, Hamo A, Carberry C, Brouwer G, Lord C.

J Autism Dev Disord. 2018 Oct;48(10):3551-3561. doi: 10.1007/s10803-018-3625-7.

PMID:
29855756
43.

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.

Krastev DB, Pettitt SJ, Campbell J, Song F, Tanos BE, Stoynov SS, Ashworth A, Lord CJ.

Nat Commun. 2018 May 22;9(1):2016. doi: 10.1038/s41467-018-04466-4.

44.

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, Lutz C, Frankum J, Song FF, Brough R, Evers B, Gogola E, Bhin J, van de Ven M, van Gent DC, Jacobs JJL, Chapman R, Lord CJ, Jonkers J, Rottenberg S.

Cell Rep. 2018 May 15;23(7):2107-2118. doi: 10.1016/j.celrep.2018.04.046.

45.

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.

Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.

46.

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.

Khalique S, Naidoo K, Attygalle AD, Kriplani D, Daley F, Lowe A, Campbell J, Jones T, Hubank M, Fenwick K, Matthews N, Rust AG, Lord CJ, Banerjee S, Natrajan R.

J Pathol Clin Res. 2018 Jul;4(3):154-166. doi: 10.1002/cjp2.103. Epub 2018 Jul 20.

47.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

48.

POMC neurons expressing leptin receptors coordinate metabolic responses to fasting via suppression of leptin levels.

Caron A, Dungan Lemko HM, Castorena CM, Fujikawa T, Lee S, Lord CC, Ahmed N, Lee CE, Holland WL, Liu C, Elmquist JK.

Elife. 2018 Mar 12;7. pii: e33710. doi: 10.7554/eLife.33710.

49.

Post-operative arterio-venous fistula blood flow influences primary and secondary patency following access surgery.

Benaragama KS, Barwell J, Lord C, John BJ, Babber A, Sandoval S, Lindsey B, Fernando B.

J Ren Care. 2018 Mar 9. doi: 10.1111/jorc.12238. [Epub ahead of print]

PMID:
29520968
50.

Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer.

Natrajan R, Tutt ANJ, Lord CJ.

Cancer Discov. 2018 Mar;8(3):272-275. doi: 10.1158/2159-8290.CD-18-0091.

Supplemental Content

Support Center